Genetic and molecular changes in ovarian cancer

被引:79
作者
Hollis, Robert L. [1 ]
Gourley, Charlie [1 ]
机构
[1] Univ Edinburgh, Edinburgh Canc Res UK Ctr, MRC Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland
基金
英国医学研究理事会;
关键词
GRADE SEROUS CARCINOMA; CLEAR-CELL CARCINOMA; FALLOPIAN-TUBE; SOMATIC MUTATIONS; INTRAEPITHELIAL CARCINOMA; GERMLINE MUTATIONS; PROGNOSTIC-FACTOR; TUMOR-SUPPRESSOR; BRCA2; MUTATIONS; TP53;
D O I
10.20892/j.issn.2095-3941.2016.0024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epithelial ovarian cancer represents the most lethal gynecological malignancy in the developed world, and can be divided into five main histological subtypes: high grade serous, endometrioid, clear cell, mucinous and low grade serous. These subtypes represent distinct disease entities, both clinically and at the molecular level. Molecular analysis has revealed significant genetic heterogeneity in ovarian cancer, particularly within the high grade serous subtype. As such, this subtype has been the focus of much research effort to date, revealing molecular subgroups at both the genomic and transcriptomic level that have clinical implications. However, stratification of ovarian cancer patients based on the underlying biology of their disease remains in its infancy. Here, we summarize the molecular changes that characterize the five main ovarian cancer subtypes, highlight potential opportunities for targeted therapeutic intervention and outline priorities for future research.
引用
收藏
页码:236 / 247
页数:12
相关论文
共 120 条
[1]   Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary [J].
Ahmed, Ashour Ahmed ;
Etemadmoghadam, Dariush ;
Temple, Jillian ;
Lynch, Andy G. ;
Riad, Mohamed ;
Sharma, Raghwa ;
Stewart, Colin ;
Fereday, Sian ;
Caldas, Carlos ;
DeFazio, Anna ;
Bowtell, David ;
Brenton, James D. .
JOURNAL OF PATHOLOGY, 2010, 221 (01) :49-56
[2]   Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas [J].
Anglesio, Michael S. ;
Kommoss, Stefan ;
Tolcher, Mary C. ;
Clarke, Blaise ;
Galletta, Laura ;
Porter, Henry ;
Damaraju, Sambasivarao ;
Fereday, Sian ;
Winterhoff, Boris J. ;
Kalloger, Steve E. ;
Senz, Janine ;
Yang, Winnie ;
Steed, Helen ;
Allo, Ghassan ;
Ferguson, Sarah ;
Shaw, Patricia ;
Teoman, Attila ;
Garcia, Joaquin J. ;
Schoolmeester, John K. ;
Bakkum-Gamez, Jamie ;
Tinker, Anna V. ;
Bowtell, David D. ;
Huntsman, David G. ;
Gilks, C. Blake ;
McAlpine, Jessica N. .
JOURNAL OF PATHOLOGY, 2013, 229 (01) :111-120
[3]  
[Anonymous], J NAT CANC I
[4]  
[Anonymous], 1993, Cancer
[5]   Ovarian Endometrioid Adenocarcinoma: Incidence and Clinical Significance of the Morphologic and Immunohistochemical Markers of Mismatch Repair Protein Defects and Tumor Microsatellite Instability [J].
Aysal, Anil ;
Karnezis, Anthony ;
Medhi, Irum ;
Grenert, James P. ;
Zaloudek, Charles J. ;
Rabban, Joseph T. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (02) :163-172
[6]  
Baldwin RL, 2000, CANCER RES, V60, P5329
[7]   Mucinous But Not Clear Cell Histology Is Associated With Inferior Survival in Patients With Advanced Stage Ovarian Carcinoma Treated With Platinum-Paclitaxel Chemotherapy [J].
Bamias, Aristotle ;
Psaltopoulou, Theodora ;
Sotiropoulou, Maria ;
Haidopoulos, Dimitrios ;
Lianos, Evangelos ;
Bournakis, Evangelos ;
Papadimitriou, Christos ;
Rodolakis, Alexandros ;
Vlahos, George ;
Dimopoulos, Meletius A. .
CANCER, 2010, 116 (06) :1462-1468
[8]   Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling [J].
Bashashati, Ali ;
Ha, Gavin ;
Tone, Alicia ;
Ding, Jiarui ;
Prentice, Leah M. ;
Roth, Andrew ;
Rosner, Jamie ;
Shumansky, Karey ;
Kalloger, Steve ;
Senz, Janine ;
Yang, Winnie ;
McConechy, Melissa ;
Melnyk, Nataliya ;
Anglesio, Michael ;
Luk, Margaret T. Y. ;
Tse, Kane ;
Zeng, Thomas ;
Moore, Richard ;
Zhao, Yongjun ;
Marra, Marco A. ;
Gilks, Blake ;
Yip, Stephen ;
Huntsman, David G. ;
McAlpine, Jessica N. ;
Shah, Sohrab P. .
JOURNAL OF PATHOLOGY, 2013, 231 (01) :21-34
[9]   Personalizing Therapy for Ovarian Cancer: BRCAness and Beyond [J].
Bast, Robert C., Jr. ;
Mills, Gordon B. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) :3545-3548
[10]   Integrated genomic analyses of ovarian carcinoma [J].
Bell, D. ;
Berchuck, A. ;
Birrer, M. ;
Chien, J. ;
Cramer, D. W. ;
Dao, F. ;
Dhir, R. ;
DiSaia, P. ;
Gabra, H. ;
Glenn, P. ;
Godwin, A. K. ;
Gross, J. ;
Hartmann, L. ;
Huang, M. ;
Huntsman, D. G. ;
Iacocca, M. ;
Imielinski, M. ;
Kalloger, S. ;
Karlan, B. Y. ;
Levine, D. A. ;
Mills, G. B. ;
Morrison, C. ;
Mutch, D. ;
Olvera, N. ;
Orsulic, S. ;
Park, K. ;
Petrelli, N. ;
Rabeno, B. ;
Rader, J. S. ;
Sikic, B. I. ;
Smith-McCune, K. ;
Sood, A. K. ;
Bowtell, D. ;
Penny, R. ;
Testa, J. R. ;
Chang, K. ;
Dinh, H. H. ;
Drummond, J. A. ;
Fowler, G. ;
Gunaratne, P. ;
Hawes, A. C. ;
Kovar, C. L. ;
Lewis, L. R. ;
Morgan, M. B. ;
Newsham, I. F. ;
Santibanez, J. ;
Reid, J. G. ;
Trevino, L. R. ;
Wu, Y. -Q. ;
Wang, M. .
NATURE, 2011, 474 (7353) :609-615